St. Louis school grants rights to nasal COVID-19 vaccine

By The Science Advisory Board staff writers

September 23, 2020 -- Precision Virologics and Bharat Biotech obtained the rights for a new chimp-adenovirus COVID-19 vaccine from Washington University School of Medicine in St. Louis.

Precision Virologics has optioned the rights to offer the intranasal vaccine in the U.S., Europe, and Japan, and Bharat has obtained a license for all other markets.

In mouse studies, a single nasal dose has shown protection against the virus. Based on these findings, the U.S. National Institutes of Health is advancing studies in nonhuman primates, according to the companies.


Copyright © 2020 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.